Vea Health review
Vea lists standard and microdose GLP-1 options alongside an iPhone app. Its own terms make the independent clinical practice responsible for prescribing decisions.
The verdict
Vea’s product selection and tracking app may appeal to someone who wants a digital care interface. Assess the medical service separately from the technology. A device or app does not establish suitability for a compounded prescription. A microdose listing does not carry the evidence of a standard obesity regimen.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
Vea Health combines online medical access, prescription products and health-tracking software. Its weight-loss collection lists semaglutide and tirzepatide in standard and microdose categories. App access is offered with treatment; hardware shown on waitlists should not be mistaken for an included device.
Who writes the prescription, and what do they see?
An independent professional practice supplies the care under Vea’s terms. A licensed clinician reviews the intake and determines medical necessity. The platform states that a consultation does not guarantee prescribing; ask which practice and clinician will manage your treatment.
Public pages describe evaluation, pharmacy shipment if approved and an app for continued tracking. The app is presented as iPhone-only at the time checked, with Android still forthcoming. Confirm how to contact the medical team if the app is unsuitable for your device.
What happens when the dose goes up?
Vea markets tailored dosing, but standard and microdose entries need separate assessment. Obtain the actual prescription strength and monitoring plan from the clinician. Neither an app trend nor an advertised category is a reason to adjust an injection yourself.
What the price includes
The collection establishes treatment choices but not one complete, recurring weight-care price for every product. The selected offer must disclose its recurring amount, cadence and any minimum term. Ask separately about clinical follow-up, prescribed supply and testing before comparing totals.
What it claims, and what it cites
Its terms explicitly discuss compounded semaglutide and tirzepatide and explain that finished compounded drugs are not FDA approved. They also permit asking about an approved alternative where clinically appropriate. Confirm the pharmacy, preparation and reason for the proposed option.
Where it holds up, and where it does not
- Strength: Independent practice role stated
- Strength: Compounded status explained in terms
- Strength: Current app limitations disclosed
- Limitation: Android access not yet established
- Limitation: Product categories do not settle an individual regimen
- Limitation: Complete recurring treatment total requires confirmation
What the evidence says about this kind of treatment
The assessment above is about Vea Health. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- An iPhone user seeking a digital tracking interface who also wants direct clarification of the clinical plan.
- Wrong for
- Someone expecting the tracking app or microdose marketing to prove medication effectiveness or clinical suitability.
The evidence behind what Vea Health prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How Vea Health compares
| Seller | Who it suits | Go |
|---|---|---|
| SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | See SkinnyRx → |
| ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | See ShedRx → |
| RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | See RxSpan MD → |
More GLP-1 telehealth sellers reviews: MyFastRxMyStart HealthNäkyNativeMedNavio MDNeo Soma Healthcare
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- Does the app prescribe a treatment?
- No. The terms place treatment decisions with licensed clinicians in an independent practice.
- Is there a five-business-day cancellation cutoff?
- The October clarification says no such cutoff applies to stopping a future renewal. Cancellation before renewal is still necessary.
Sources for this review
Provider information checked . Terms can change.